Nuocheng Jianhua will announce the clinical data of the pan-FGFR inhibitor gunagratinib at the annual meeting of the American Society of Clinical Oncology in 2021

Biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) today announced that the company's pan-FGFR inhibitor gunagratinib (ICP-192) clinical data will be announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting , And was selected to be displayed in the form of a poster.
This is also the first time that gunagratinib has presented clinical data at an international academic conference.
The abstract will be published on ASCO's official website on May 19th, US time
.

The 2021 ASCO Annual Meeting will be held online from June 4 to 8, 2021
.
The ASCO annual meeting is the most important and authoritative academic exchange event in the global oncology field, which will showcase the current international cutting-edge clinical oncology scientific research results and tumor treatment technologies

Nuocheng Jianhua will present the latest clinical progress of gunagratinib at the ASCO annual meeting
.
ICP-192 is a class 1 innovative drug with global independent intellectual property rights under Nuocheng Jianhua.

Selected study: Phase I clinical results of a highly selective irreversible FGFR inhibitor ICP-192 (gunagratinib) for patients with advanced solid tumors with abnormal FGFR genes